Merck Chairman and CEO Robert Davis joins 'Mad Money' host Jim Cramer at the JPMorgan Healthcare Conference to talk recent acquisitions, growth in its vaccine segment, opportunities in China and more.

I think that Rob Davis at Merck, that's been a one-way stock. Down. Even though he's done some terrific things. He's got a great heart drug. But it doesn't seem to matter at all." Overall MRK ...

In an interview on CNBC’s Mad Money, Robert Davis said Merck’s (MRK) current pipeline is the most diversified it has been in recent history. “We’re not just a Keytruda company, we’re an ...

Merck CEO Rob Davis told CNBC's Jim Cramer that there's more to the pharmaceutical giant than its lucrative cancer drug, Keytruda, and he described other ventures in its portfolio. "Keytruda has ...

Both Merck & Co. and Halozyme are holding their ground in a freshly unveiled patent dispute surrounding the New Jersey pharma ...

Merck (NYSE:MRK) shares were on track to snap six straight sessions of gains on Wednesday, as the stock fell 2.8% at $88.87 ...

Merck is bracing for the years of sales growth from oncology superstar Keytruda to take a sharp turn in 2028—and for more ...